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Abstract
Background: Humoral immune responses play a key role in the development of immunity to malaria, but the host
genetic factors that contribute to the naturally occurring immune responses to malarial antigens are not
completely understood. The aim of the present investigation was to determine whether, in subjects exposed to
malaria, GM and KM allotypes–genetic markers of immunoglobulin g and -type light chains, respectively–
contribute to the magnitude of natural antibody responses to target antigens that are leading vaccine candidates
for protection against Plasmodium vivax.
Methods: Sera from 210 adults, who had been exposed to malaria transmission in the Brazilian Amazon endemic
area, were allotyped for several GM and KM determinants by a standard hemagglutination-inhibition method. IgG
subclass antibodies to P. vivax apical membrane antigen 1 (PvAMA-1) and merozoite surface protein 1 (PvMSP1-19)
were determined by an enzyme-linked immunosorbent assay. Multiple linear regression models and the non-
parametric Mann-Whitney test were used for data analyses.
Results: IgG1 antibody levels to both PvMSP1-19 and PvAMA-1 antigens were significantly higher (P = 0.004,
P = 0.002, respectively) in subjects with the GM 3 23 5,13,14 phenotype than in those who lacked this phenotype.
Conclusions: Results presented here show that immunoglobulin GM allotypes contribute to the natural antibody
responses to P. vivax malaria antigens. These findings have important implications for the effectiveness of vaccines
containing PvAMA-1 or PvMSP1-19 antigens. They also shed light on the possible role of malaria as one of the
evolutionary selective forces that may have contributed to the maintenance of the extensive polymorphism at the
GM loci.
Background
Malaria is present in nearly 90 countries with approxi-
mately 2.5 billion people exposed to infection by Plasmo-
dium falciparum and Plasmodium vivax [1]. Although
causing less mortality than P. falciparum, P. vivax infec-
tion has an enormous socioeconomic impact. P. vivax is
a widely distributed human malarial parasite, prevalent in
South America, Asia and Oceania, and the 70-80 million
cases currently recorded annually are of global public
health importance [2]. Plasmodium vivax is now recog-
nized as a cause of severe and fatal malaria, despite its
low parasitaemia, the increased deformability of vivax-
infected red blood cells and an apparent paucity of para-
site sequestration [3]. The most cost-effective measure to
control infectious diseases like malaria is a vaccine and
effective malaria vaccines are still not available. Antigens
of Plasmodium located on the surface or in the apical
organelles of merozoites have been characterized as tar-
gets for protection or as possible vaccine antigens against
malaria [4]. Among them, the apical membrane antigen 1
(AMA-1) and a 19-kDa fragment of merozoite surface
protein-1 (MSP1-19) are the leading candidates for
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inclusion in a vaccine against blood stages of malaria.
AMA-1 is an 83-kDa antigen synthesized during the
mature stages of the parasite; it is thought to be involved
in the process of erythrocyte invasion [4]. MSP1-19 is a
portion of MSP1 produced after two processing steps
and remains attached to the newly formed ring stage
parasite after invasion [5]. Active immunization of
experimental animals with either native or recombinant
forms of both proteins has been shown to be protective
against challenge infection [6]. Moreover, antibodies to
MSP1-19 and AMA-1 inhibited invasion of red blood
cells [7].
Humoral immune responses, which have a substantial
genetic component [8], play a key role in the develop-
ment of immunity to malaria. Identification and under-
standing of the mechanisms of action of host genetic
factors that contribute to the naturally occurring anti-
malarial immune responses is of utmost importance.
The current paucity of knowledge in this area hinders
effective immunological intervention and confounds the
evaluation of ongoing vaccine efficacy trials. The few
immune response genes identified thus far do not
account for the total inter-individual variability in anti-
body responsiveness to malarial antigens [9,10], implying
the involvement of additional genes. Immunoglobulin
(Ig) allotypes are important candidates for controlling
immune responsiveness, as evidenced by their associa-
tion with humoral immunity to a variety of pathogens
[11-16]. The role these polymorphic determinants play
in antibody responses to malarial antigens, however, is
not fully understood.
There are striking qualitative and quantitative differ-
ences in the distribution of Ig GM and KM allotypes
among different ethnic groups [17,18]. Additionally,
there is almost complete linkage disequilibrium between
particular GM determinants within an ethnic group, and
every major group is characterized by a distinct array of
GM haplotypes. These population genetic properties
suggest that differential selection over many generations
may have played an important role in the maintenance
of polymorphism at these loci, but the nature of putative
evolutionary selective forces is not understood. As first
suggested by J.B.S. Haldane, major infectious diseases
like malaria, which probably coevolved with humans,
have been the principal selective forces of natural selec-
tion [19]. One mechanism for how GM and KM deter-
minants could contribute to the outcome of infection
with various agents may be through allotype-restricted
antibody responses to these pathogens, resulting in dif-
ferential immunity to infectious diseases. The aim of the
present investigation was to determine whether, in sub-
jects exposed to malaria, GM and KM allotypes contri-
bute to the magnitude of natural antibody responses to
certain target antigens that are leading vaccine candi-
dates for protection against P. vivax.
Methods
Subjects
The study population, derived from four sites and
described in detail elsewhere [20,21], consisted of 210
non-infected (negative thick blood smears) adults who
had been exposed to malaria hypo-mesoendemic trans-
mission in the Brazilian Amazon area and reported a
variable number of previous episodes caused by P. vivax
or P. falciparum with clinical symptoms. The first group
of subjects lived in Belém, the capital of Pará State. It
was composed of 76 persons (median age, 29 years) who
had acquired a single P. vivax malaria after a brief expo-
sure (a few days) on the island of Cotijuba, which is
located 25 km from Belém. The second group lived in
Cuiabá, the capital of Mato Grosso, where no malaria
transmission occurs. It was composed of 20 persons
(median age, 33 years) who had become infected after
short visits to mining and/or agricultural areas in the
northern part of the state where malaria is endemic.
They stayed less than one year in the transmission
areas. The third group was composed of 65 persons
(median age, 31 years) who had resided for more than
10 years in Terra Nova do Norte (TNN), a small rural
community within the malaria endemic region. These
individuals were continuously exposed to malaria trans-
mission (median time, 10.5 years). The fourth group was
composed of 49 persons who had lived for approxi-
mately 20 years in several gold-mining areas in the Bra-
zilian Amazon basin. All lived in Apiacás, a municipality
located in northern Mato Grosso State. Apiacás was
characterized as a mesoendemic area because malaria
prevalence in 1996, the study year, was 18%.
A complete health questionnaire was applied to all parti-
cipants. Ethical clearance for this study was obtained from
the Institutional Review Boards of the Federal University
of Minas Gerais, Brazil and the Medical University of
South Carolina, USA. Venous blood samples (2 mL) were
drawn into EDTA containing tubes and used to obtain
plasma which were frozen at -20°C for subsequent use.
Antigens
Two recombinant proteins of P. vivax were employed in
this investigation. Recombinant apical membrane anti-
gen 1 (PvAMA-1), which contains the amino acid
sequence 43-487 of the ectodomain of the P. vivax BEL-
12 isolate, was expressed in Escherichia coli and purified
as described previously [22]. The recombinant merozoite
surface protein 1 (PvMSP1-19), which represents the
amino acid sequence of the two EGF-like motifs of the
Belem strain, was expressed in Escherichia coli in fusion
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with the glutathione S-transferase gene as described
previously [23,24].
Antibody determinations
IgG subclass determinations were made by an ELISA
described elsewhere [20,21]. Briefly, the concentration of
PvMSP1-19 and PvAMA-1 used were 0.5 μg/ml and
1.0 μg/mL, respectively. All samples were diluted
1:50. Mouse monoclonal antibodies to human IgG
subclasses used were clone HP-6012 for IgG1, clone
HP-6014 for IgG2, clone HP-6010 for IgG3, and clone
HP-6025 for IgG4 (Sigma) diluted according to the
manufacturer’s specifications. Monoclonal antibody
binding was detected with peroxidase conjugated anti-
mouse immunoglobulin (Sigma). The threshold of posi-
tivity (cut-off value) was obtained by testing 40 different
negative control sera from individuals not exposed to
malaria from Belo Horizonte. The mean optical density
value at 490 nm (OD490) ± 3 SD for duplicate determi-
nations in negative sera was used as the cut-off value
for different subclasses. The reactivity index (RI) was
obtained to compare the levels of IgG subclasses among
the subjects. The RI value was calculated by dividing the
mean OD value for each test sample assayed by the cut-
off value for each subclass tested using sera from
healthy individuals (control group). Samples with an RI
> 1 were considered positive.
GM and KM allotyping
Serum samples were typed for G1 M (1/a, 2/x, 3/f, 17/z),
G2 M (23/n), G3 M (5/b1, 6/c3, 13/b3, 14/b4, 21/g), and
KM (1, 3) allotypes by a standard hemagglutination-inhi-
bition method [25]. In brief, a mixture containing human
blood group ORh+ erythrocytes coated with anti-Rh anti-
bodies of known GM/KM allotypes, the test sera, and
monospecific anti-allotype antibodies were incubated in a
microtitre plate. Test sera containing IgG of particular
allotype inhibited hemagglutination by the anti-allotype
antibody, whereas negative sera did not. As mentioned
before, linkage disequilibrium (allelic association) in the
GM system is almost absolute and the determinants are
transmitted as a group called haplotypes [26]. The nota-
tion follows the international system for human gene
nomenclature [27], in which haplotypes and phenotypes
are written by grouping together the markers that belong
to each IgG subclass, by the numerical order of the mar-
ker and of the subclass; markers belonging to different
subclasses are separated by a space, while allotypes within
a subclass are separated by commas.
Statistical analyses
Antibody levels against PvAMA-1 or PvMSP1-19 were
described as median and interquartile range for all IgG
subclasses. The allotype data were analysed as a group
(phenotypes), rather than the presence or absence of
individual markers, as the significant linkage disequili-
brium in this system may be the result of certain selec-
tive evolutionary advantages (against immunity to
pathogens like malaria), making the analysis by pheno-
types biologically more meaningful. Subjects with very
unusual GM phenotypes and those whose frequency
was <3% were combined as “other” for statistical ana-
lyses, so as not to have a test with too many degrees of
freedom or categories with cell counts too small for
appropriate analyses. This method of grouping increases
statistical power and makes use of all data. In univariate
analyses, the non-parametric Mann-Whitney test was
used to determine whether GM and KM phenotypes
were associated with anti-P. vivax IgG isotype-specific
antibody levels (reactivity index). Subsequently, multiple
linear regression models were used to investigate the
independent contribution of cumulative exposure to
malaria (according to the study site) to GM and KM
phenotype distribution and antibody responses. Thus,
phenotypes associated with levels of antibodies against
PvMSP1-19 and PvAMA-1 using the Mann-Whitney
univariate analyses were also included in multiple linear
regression analysis by study sites. In all models, statisti-
cal significance was defined as P < 0.05.
Results
The distribution of GM and KM phenotypes in relation
to IgG subclass antibody levels to PvMSP1-19 and
PvAMA-1 is given in Tables 1 and 2, respectively. Of the
entire study population, 26 subjects could not be charac-
terized for antibodies to PvMSP1-19, reflecting the differ-
ences in the total number of individuals in the two tables.
The majority of the GM phenotypes observed could be
explained by postulating the segregation of common
Caucasoid (GM 1,17 21, GM 1,2,17 21, GM 3 5,13,14 and
GM 3 23 5,13,14) and Negroid (GM 1,17 5,6, GM 1,17
5,14, GM 1,17 5,6,14, and GM 1,17 5,13,14) haplotypes.
IgG1 antibody responses to both PvMSP1-19 (Table 1)
and PvAMA-1 (Table 2) were highly significantly asso-
ciated with the GM 3 23 5,13,14 phenotype. For
PvMSP1-19, carriers of the GM 3 23 5,13,14 phenotype
had higher levels of IgG1 than noncarriers (median
[interquartile age, IQR]: 3.60 RI [1.89-4.71] versus 1.59
RI [0.18-3.36], P = 0.004). This association was even
more pronounced for antibody responses to PvAMA-1:
carriers of the GM 3 23 5,13,14 phenotype had higher
levels of IgG1 than noncarriers: 3.81 RI [1.18-11.78] ver-
sus 0.67 RI [0.20-2.13], P = 0.002). No significant inter-
actions between GM and KM phenotypes were found
for antibody responsiveness to either PvAMA-1 or
PvMSP1-19 antigens. As presented in the footnotes of
Tables 1 and 2, the results of the univariate analyses
showed several significant associations between GM and
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KM phenotypes and antibody responsiveness, but after
analyses using the multiple linear regression models
and controlling for the study sites (different levels of
cumulative exposure to malaria), only the GM 3 23
5,13,14 phenotype showed an independent and positive
association with the level of IgG1 anti-malarial antibo-
dies (regression coefficient 1.03 [95% CI 0.13-1.93],
P = 0.025 and regression coefficient 4.56 [95% CI 2.78-
6.34], P = 0.000 for PvMSP1-19 and PvAMA-1,
respectively).
Discussion
A number of studies have shown that anti-malarial anti-
bodies of IgG1 subclass contribute significantly to pro-
tective immunity against malaria [28,29]. A major
finding of the present investigation is that IgG1 antibody
levels to both PvMSP1-19 and PvAMA-1 antigens were
significantly higher in subjects with the GM 3 23
5,13,14 phenotype than in those who lack this pheno-
type. Several mechanisms could account for these obser-
vations. One mechanism might involve GM allotypes




Antibody levels (Reactivity Index) (Median, Interquartile range)
IgG1 IgG2 IgG3 IgG4
GM 1,2,17 21 (9) 0.63(0.01-2.67) 0.05(0.01-0.21) 0.35(0.01-1.53) 0.01(0.01-0.18)
GM 1,17 5,13,14,21 (15) 0.87(0.55-1.97) 0.29(0.01-0.82) 1.66(0.01-6.31) 0.44(0.01-0.58)
GM 1,2,3,17 23 5,13,14,21 (13) 2.65(0.32-4.26) 0.33(0.01-0.46) 3.17(0.44-5.25) 0.11(0.01-0.48)
GM 1,3,17 23 5,13,14,21 (28) 0.76(0.01-3.57) 0.11(0.00-0.40) d0.15(0.01-2.74) 0.09(0.01-0.52)
GM 1,3,17 23 5,6,13,14 (10) 1.88(1.49-3.37) 0.16(0.02-0.50) 0.47(0.02-2.40) 0.09(0.01-0.23)
GM 1,3,17 5,13,14,21 (18) 2.55(0.21-4.07) 0.31(0.06-1.54) 1.68(0.01-4.46) f0.30(0.01-0.99)
GM 3 23 5,13,14 (20) b3.60(1.89-4.71) 0.16(0.03-1.25) 2.49(0.25-5.81) 0.08(0.01-0.58)
aOther GM (71) 2.27(0.25-3.31) 0.28(0.01-0.67) 1.44(0.08-5.06) 0.17(0.01-0.43)
KM 1 (9) 1.18(0.01-2.44) c0.02(0.01-0.16) e0.01(0.01-2.35) 0.01(0.01-0.46)
KM 1,3 (68) 1.75(0.53-3.48) 0.18(0.00-0.64) 1.44(0.13-5.81) 0.19(0.01-0.56)
KM 3 (107) 2.32(0.18-3.86) 0.22(0.01-0.68) 1.53(0.06-3.83) 0.13(0.01-0.40)
aOther GM [(GM 1,17 21 (n = 5), GM 1,17 5,6,14,21 (n = 5), GM 3 5,13,14 (n = 4), GM 1,17 13,21 (n = 5), GM 1,17 6,14,21 (n = 1), GM 1,2,17 13,21 (n = 4), GM
1,2,17 13,14,21 (n = 2), GM 1,3,17 13,14,21 (n = 1), GM 1,17 23 5,13,14,21 (n = 1), GM 1,17 5,6,13,14 (n = 4), GM 1,17 5,6,13,14,21 (n = 4), GM 1,17 5,14,21 (n = 2),
GM 1,2,17 5,6,13,14,21 (n = 1), GM 1,2,17 5,6,14,21 (n = 4), GM 1,2,17 5,6,21 (n = 2), GM 1,2,3,17 5,6,13,14,21 (n = 1), GM 1,3,17 23 5,6,13,14,21 (n = 5), GM 1,3,17
5,13,14 (n = 4), GM 1,3,17 5,6,13,14 (n = 5), GM 1,3,17 5,6,13,14,21 (n = 3), GM 1,2,17 5,13,14,21 (n = 3), GM 1,2,3,17 5,13,14,21 (n = 5)]
bsignificantly higher (P = 0.004), csignificantly lower (P = 0.031), dsignificantly lower (P = 0.051),
esignificantly lower (P = 0.027), fsignificantly higher (P = 0.002), (obtained by Wilcoxon-Mann-Whitney test) compared with the rest of the GM phenotypes.
Table 2 GM/KM phenotypes in relation to IgG subclass-specific antibodies to PvAMA-1 in subjects exposed to malaria
Phenotypes
(Number of subjects)
Antibody levels (Reactivity Index) (Median, Interquartile range)
IgG1 IgG2 IgG3 IgG4
GM 1,2,17 21 (10) b0.15(0.10-0.48) 0.02(0.01-0.62) 0.57(0.18-1.04) 0.06(0.01-0.64)
GM 1,17 5,13,14,21 (21) c0.28(0.05-0.58) 0.4(0.05-1.21) 0.47(0.24-1.05) 0.37(0.05-0.75)
GM 1,2,3,17 23 5,13,14,21 (14) 1.09(0.54-3.70) 0.42(0.16-0.88) 0.45(0.26-0.73) 0.23(0.03-0.38)
GM 1,3,17 23 5,13,14,21 (33) d2.02(0.61-3.67) 0.50(0.16-1.23) 0.66(0.31-1.72) 0.58(0.13-0.93)
GM 1,3,17 23 5,6,13,14 (10) 1.68(0.22-3.83) 0.01(0.01-0.30) 0.31(0.01-1.10) 0.60(0.01-0.91)
GM 1,3,17 5,13,14,21 (20) 0.94(0.18-3.98) 0.35(0.01-0.92) 0.47(0.09-1.86) 0.27(0.06-0.92)
GM 3 23 5,13,14 (22) e3.81(1.18-11.78) 0.45(0.01-1.71) 0.76(0.12-1.32) 0.15(0.01-2.30)
aOther GM (80) f0.58(0.11-2.09) 0.39(0.13-1.66) 0.59(0.18-1.09) 0.32(0.03-0.87)
KM 1 (11) 0.71(0.03-1.10) 0.13(0.01-0.44) 0.28(0.10-0.82) 0.47(0.38-0.95)
KM 1,3 (80) 0.67(0.27-1.96) 0.49(0.14-1.09) 0.57(0.23-1.06) 0.33(0.04-0.69)
KM 3 (119) 0.94 (0.19-3.69) 0.37(0.01-1.06) 0.57(0.21-1.14) 0.29(0.03-0.85)
aOther GM [(GM 1,17 21 (n = 5), GM 1,17 5,6,14,21 (n = 5), GM 3 5,13,14 (n = 4), GM 1,17 13,21 (n = 5), GM 1,17 6,14,21 (n = 1), GM 1,2,17 13,21 (n = 5), GM
1,2,17 13,14,21 (n = 3), GM 1,3,17 13,14,21 (n = 2), GM 1,17 23 5,13,14,21 (n = 2), GM 1,17 5,6,13,14 (n = 5), GM 1,17 5,6,13,14,21 (n = 4), GM 1,17 5,14,21 (n = 2),
GM 1,2,17 5,6,13,14,21 (n = 2), GM 1,2,17 5,6,14,21 (n = 4), GM 1,2,17 5,6,21 (n = 2), GM 1,2,3,17 5,6,13,14,21 (n = 1), GM 1,3,17 23 5,13,14 (n = 1), GM 1,3,17 23
5,6,13,14,21 (n = 5), GM 1,3,17 5,13,14 (n = 5), GM 1,3,17 5,6,13,14 (n = 5), GM 1,3,17 5,6,13,14,21 (n = 3), GM 1,2,17 5,13,14,21 (n = 4), GM 1,2,3,17 5,13,14,21
(n = 5)]
bsignificantly lower (P = 0.019), csignificantly lower (P = 0.0003), dsignificantly higher (P = 0.007), esignificantly higher (P = 0.002), fsignificantly lower (P = 0.029)
(obtained by Wilcoxon-Mann-Whitney test) compared with the rest of the GM phenotypes.
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being part of the recognition structures for PvMSP1-19
and PvAMA-1 antigens. Memory B cells, which predo-
minantly express IgG as the membrane-bound form of
Ig, show enhanced response to antigen stimulation than
cells expressing IgM on their surface [30,31]. Perhaps
membrane-bound IgG molecules with the GM 3 23
5,13,14 phenotype are more efficient in the uptake, pro-
cessing, and subsequent presentation of PvMSP1-19 and
PvAMA-1 epitopes to the collaborating T cells, resulting
in strong humoral immunity.
Additionally, GM allotypes could contribute to anti-
body responsiveness through their direct or indirect
involvement in antibody specificity. There is growing
body of evidence for the involvement of these constant-
region determinants in antibody specificity usually asso-
ciated with the variable region of the Ig molecule [32].
Possible mechanisms include direct contribution to the
formation of idiotypic determinants, modulation of anti-
body binding affinity, and linkage disequilibrium with
alleles coding for the variable-region epitopes [33-36].
The possibility of GM allotype involvement in malarial
immunity was suggested by the results of a previous inves-
tigation, which showed significant differences in the fre-
quencies of these determinants between two African
sympatric tribes–Fulani and Masaleit–with marked differ-
ences in susceptibility to P. falciparum malaria [37]. A
recent study has reported significant associations between
particular GM phenotypes and clinical presentation of
P. falciparum malaria in Beninese children [38]. In a popu-
lation from Sudan, GM phenotypes were found to be asso-
ciated with susceptibility to P. falciparum malaria and with
antibody responsiveness to malarial antigens [39]. The
Sudanese study, however, is not comparable to the present
study employing subjects from Brazil. In addition to the
differences in the pathogen (P. falciparum vs P. vivax),
there are highly significant differences in the frequency of
GM/KM allotypes between the two populations (26). For
instance, none of the Sudanese subjects possessed the GM
3 23 5,13,14 Phenotype, which is associated with antibody
responsiveness in the present study, underscoring the
necessity of studying different populations.
Because malaria is a major global health problem, there
is clear urgency to develop a vaccine for protection against
infection. Development of an effective vaccine, however,
would require a thorough understanding of the mechan-
isms associated with immunity to this parasite. Further-
more, given the complexity of the malarial parasite and
tremendous genetic diversity of human populations, it
may be difficult to devise one vaccine that is effective
against all variants of the parasite and provides protective
immunity for all people. Studies of the kind reported here
might be able to identify people who are more likely to
respond to a given vaccine. For the subjects with non-
responders genotypes, the vaccine could be fused with
appropriate adjuvants to circumvent the allotypic restric-
tion in immune responsiveness. There is precedence for
converting genetic non-responders into responders to a
given vaccine. For instance, subjects classified as non-
responders to Haemophilus influenzae type b polysacchar-
ide vaccine–based on their GM 23 and KM 1 allotype sta-
tus–became responders when the vaccine was conjugated
to a suitable adjuvant [40-42]. The mechanism underlying
the circumvention of allotype-associated differences in
antibody responses is not understood. Ability to identify
potential responders to a given vaccine would be consider-
ably enhanced by simultaneous examination of other
genes of the immune system, such as HLA, FcgRIIa,
FcgRIIIa, TNF, which have been shown to make significant
contributions to malarial immunity. Genes do not act in
isolation: there is growing body of evidence that epistasis–
modification of the action of a gene by one or more other
genes–plays a significant role in human diseases [43].
Therefore, it is important to investigate the role of possible
allelic associations between candidate genes in influencing
various parameters of immunity to malaria. For instance,
GM allotypes may influence antibody-dependent cellular
inhibition (ADCI) and phagocytosis of malarial parasites
by their differential interaction with FcgR expressed on
effector cells. The majority of GM epitopes are present on
the Fc portion of the IgG molecule. Thus, Fc of a particu-
lar GM genotype could preferentially bind to the FcgRIIa
or FcgRIIIa of a particular genotype and influence immu-
nity to malaria through ADCI, which is one of the most
efficient mechanisms through which antibodies protect
against malaria. This preferential ligand-receptor interac-
tion would be analogous to the reported interaction
between particular killer cell immunoglobulin-like recep-
tors and their HLA-C ligand in the resolution of hepatitis
C virus infection [44]. Such studies would require large
study populations and collaboration of several research
centers.
Although plausible mechanisms of direct involvement of
GM allotypes in humoral immunity to malaria are dis-
cussed here, the associations observed in this study could
also result from linkage disequilibrium between as-yet-uni-
dentified putative immune response gene(s) for PvMSP1-
19 and PvAMA-1 antigens and particular GM alleles.
Therefore, it is important to expand these studies to
include other ethnic groups, characterized by a different
array of GM haplotypes, resulting from ethnic differences
in linkage disequilibrium among GM alleles [26]. This is
the first report of association between GM allotypes and
antibody responsiveness to P. vivax malarial antigens.
Conclusions
Anti-malarial antibodies of IgG1 subclass have been pre-
viously shown to contribute significantly to protective
immunity against malaria. Results presented here show
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that IgG1 antibody levels to P. vivax PvMSP1-19 and
PvAMA-1 antigens were significantly higher in subjects
with the GM 3 23 5,13,14 phenotype than in those who
lacked this phenotype. If these findings were confirmed
in an independent study, they could aid in identifying
subjects (GM 3 23 5,13,14) who are more likely to bene-
fit from PvMSP1-19 and PvAMA-1 containing vaccines.
For the non-carriers of GM 3 23 5,13,14, these antigens
could be fused with appropriate adjuvants to circumvent
the allotypic restriction in immune responsiveness.
The nature of the evolutionary selective mechanism(s)
that maintains polymorphisms at the GM loci is not
known. Strong associations between GM allotypes and
antibody levels to malarial antigens suggest that malaria
may have been one of the selective forces that have con-
tributed to the maintenance of the balanced polymorph-
ism at these loci.
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